STOCK TITAN

Cytek Biosciences, Inc. - CTKB STOCK NEWS

Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.

Cytek Biosciences, Inc. (CTKB) delivers advanced cell analysis solutions through its patented Full Spectrum Profiling technology, serving research institutions and biotech organizations worldwide. This page provides investors and industry professionals with direct access to official company announcements and relevant news updates.

Discover the latest developments including product innovations, financial results, strategic partnerships, and regulatory milestones. Our curated collection ensures you stay informed about CTKB’s progress in advancing high-resolution cellular analysis tools for scientific research.

Key updates cover earnings reports, technology enhancements, executive leadership changes, and market expansion initiatives. All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Cytek Biosciences’ evolving story in life sciences innovation. Check back regularly for real-time updates that matter to stakeholders in the biotech investment community.

Rhea-AI Summary
Cytek Biosciences to report Q3 2023 financial results on November 7th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
conferences earnings
-
Rhea-AI Summary
Cytek Biosciences receives EN ISO 13485:2016 Quality Management System certification, validating commitment to quality in all areas. Plans to focus on translational and clinical markets. Certification represents first step to enter U.S. clinical market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
Rhea-AI Summary
Cytek Biosciences to showcase its cell analysis solutions at ESCCA 2023 and ICCS Meeting & Course. Dr. Manuel Ramirez to lead symposium on optimizing a 24-color B cell panel. Lunch and Learn presentation on panel design and assay optimization. Positive for stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences launches global roadshow called Cytek Reveal to expand knowledge of spectral flow cytometry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences to participate in Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
Rhea-AI Summary
Cytek Biosciences appoints Philippe Busque as SVP of Global Sales & Services, enhances sales organization and creates a new platform organization. Acquisition of Amnis and Guava product lines provides expanded market access and new product development opportunities. Chief Commercial Officer Todd Garland is leaving for another opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
management
-
Rhea-AI Summary
Cytek Biosciences to participate in UBS MedTech, Tools and Genomics Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences earnings
Cytek Biosciences, Inc.

Nasdaq:CTKB

CTKB Rankings

CTKB Stock Data

467.56M
116.54M
8.9%
61.33%
2.69%
Medical Devices
Laboratory Analytical Instruments
Link
United States
FREMONT